SHANGHAI — Chinese drugmaker Innovent Biologics announced Tuesday that it has reached a deal giving it exclusive rights to market and sell Eli Lilly’s breast cancer treatment Verzenios throughout mainland China.
Under the terms of the agreement, Innovent will handle all commercialization of the drug in the Chinese market, while Eli Lilly will remain responsible for producing, supplying, and advancing the development of Verzenios.
